The estimated Net Worth of Enterprise Associates 14, L... is at least $21.2 Milion dollars as of 28 August 2019. Enterprise L owns over 1,211 units of Mersana Therapeutics Inc stock worth over $21,168,350 and over the last 5 years Enterprise sold MRSN stock worth over $3,524.
Enterprise has made over 1 trades of the Mersana Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Enterprise sold 1,211 units of MRSN stock worth $3,524 on 28 August 2019.
The largest trade Enterprise's ever made was selling 1,211 units of Mersana Therapeutics Inc stock on 28 August 2019 worth over $3,524. On average, Enterprise trades about 1,211 units every 0 days since 2019. As of 28 August 2019 Enterprise still owns at least 11,959,520 units of Mersana Therapeutics Inc stock.
You can see the complete history of Enterprise L stock trades at the bottom of the page.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: